Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Adagene dosed the first patient in a Phase 1 study combining its masked anti-CTLA-4 SAFEbody muzastotug with Incyte's TGFβR2 × PD-1 bispecific INCA33890 in third-line MSS colorectal cancer patients, including those with liver metastases. Under the collaboration first announced in April 2026, Incyte is sponsoring and conducting the study while Adagene supplies clinical muzastotug.
Key figures
- Drug Name
- muzastotug (ADG126)
- Phase Of Trial
- Phase 1
- Study design
- open-label dose escalation and expansion
- Patient population
- third-line MSS colorectal cancer, with and without liver metastases
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.